Department of Pharmacy, Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, USA.
Department of Pediatrics, Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, USA.
J Clin Pharm Ther. 2021 Apr;46(2):524-527. doi: 10.1111/jcpt.13316. Epub 2020 Nov 25.
Our objective is to report a paediatric case of high-level ceftaroline resistance without previous ceftaroline exposure.
A 20-month-old, 12 kg, female with invasive MRSA infection presented with high-level ceftaroline resistance with no previous ceftaroline exposure.
To our knowledge, our case is the first report of high-level ceftaroline resistance evident in a paediatric patient with invasive infection due to MRSA, without history of prior ceftaroline exposure. This case illustrates the importance of weighing the risk of resistance with the benefits of use when starting therapy empirically prior to susceptibility results, even in patients without previous drug exposure.
已知情况
我们的目的是报告一例无先前头孢洛林暴露的儿童高水平头孢洛林耐药病例。
一名 20 个月大、12 公斤重的女性患有侵袭性 MRSA 感染，表现出高水平头孢洛林耐药，无先前头孢洛林暴露史。
据我们所知，我们的病例是首例报道的儿童侵袭性感染 MRSA 导致的高水平头孢洛林耐药病例，且无先前头孢洛林暴露史。该病例表明，在获得药敏结果之前，即使是无先前药物暴露的患者，在经验性开始治疗时，权衡耐药风险与获益非常重要。
